ACHV
Achieve Life Sciences, Inc. (NASDAQ)
Healthcare — Biotechnology
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Strong Buy
1.2 / 5
10 analysts
$6.40
(0.00%)
Target:
$13.80
(115.6%)
Sign in to add ACHV to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $670.36M |
| P/E Ratio (TTM) | - |
| Forward P/E | -13.21 |
| EPS (TTM) | $-1.07 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -496.15% |
| Debt/Equity | 140.03 |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $13.80 |
| Analysts | 10 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 65.1 |
| Beta | 2.26 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $6.55 |
| 52-Week Low | $2.02 |
| 50-Day Avg | $5.01 |
| 200-Day Avg | $4.41 |
| Avg Volume | $1.95M |
| Volume | $1.71M |
Performance Analysis
BULLISHACHV shows predominantly bullish signals based on its fundamentals and technicals.
-
Trading near its 52-week high ($6.55), which may indicate limited upside.
+
RSI at 65.1 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Wall Street consensus is "Strong Buy" from 10 analysts.
+
Average analyst target of $13.80 implies 115.6% upside.
Recent News
Loading news...
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report